Displaying drugs 14726 - 14750 of 15117 in total
Giloralimab
Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and …
Volrustomig
Volrustomig is under investigation in clinical trial NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma).
Investigational
Lacripep
Lacripep is under investigation in clinical trial NCT03226444 (Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome).
Investigational
Vilamakitug
Vilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine).
Investigational
SGN-B6A
Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
Acasunlimab
Acasunlimab is under investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer).
Investigational
Petosemtamab
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Rezpegaldesleukin
Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)).
Investigational
Povetacicept
Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).
Investigational
Pegtarviliase
Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency).
Investigational
Mivelsiran
Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).
Investigational
Imdusiran
Imdusiran is under investigation in clinical trial NCT06245291 (Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection).
Investigational
4-(1H-IMIDAZOL-1-YL)PHENOL
Experimental
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion …
BF-37
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … BF-37 for the treatment of atopic dermatitis and/or psoriasis. …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and …
JPC-3210
JPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable preclinical pharmacokinetics including a lengthy plasma elimination half-life.
Experimental
Matched Description: … multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and …
Prolectin-M
Prolectin-M is a (1-6)-alpha-D-mannopyranose and acts as an antagonist of galectin. It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Investigational
Matched Description: … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. …
Elsubrutinib
Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).
Investigational
Matched Description: … under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and …
Displaying drugs 14726 - 14750 of 15117 in total